Palvella Therapeutics, Inc.
PVLA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$125.10
KIRA · Stoqly’s AI analyst, in plain words
- Palvella Therapeutics, Inc. had $2.6M of revenue in fiscal 2025, up 303.4% on the year before. Over five years, revenue changed −38.5% a year on average.
- Its operating margin was −1,490.4%, up 705.1 pts: of every 100 in sales, about −1,490 is left after running the business.
- Palvella Therapeutics, Inc. lost $41.7M in fiscal 2025.
Market cap
$1.8B
P/E
—
Revenue
$2.6M
Net income
−$41.7M
Free cash flow
—
Operating margin
−1,490.4%
Palvella Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+303.4%
Yes. Sales grew 303.4% last year.
Does it make a profit?
−1,610.6%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Palvella Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- PALVELLA THERAPEUTICS, INC.
- CIK
- 0001583648
Palvella Therapeutics, Inc. · PVLA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $31.4M | $25.9M | $42.8M | $0.6M | $2.6M |
| Revenue growth | 7.1% | −17.6% | 65.3% | −98.5% | 303.4% |
| Net interest income | — | — | — | $0.6M | $2.6M |
| Operating margin | −165.0% | −167.8% | −27.7% | −2,195.5% | −1,490.4% |
| Net income | −$45.7M | −$33.3M | $18.7M | −$17.4M | −$41.7M |
| Net margin | −145.6% | −128.5% | 43.7% | −2,715.6% | −1,610.6% |
| Diluted EPS | −$0.71 | — | $2.17 | −$7.83 | −$3.71 |
| Cash | |||||
| Cash from operations | −$7.7M | −$59.9M | −$13.7M | −$10.8M | −$25.0M |
| Capital expenditure | $0.9M | $1.0M | $0.2M | — | — |
| Free cash flow | −$8.6M | −$61.0M | −$13.9M | — | — |
| FCF margin | −27.4% | −235.4% | −32.4% | — | — |
| Share count change | 18.5% | — | — | 24.1% | 405.5% |
| Debt and strength | |||||
| Cash and short-term investments | $118M | $59.2M | $16.3M | $83.6M | $58.0M |
| Shareholders' equity | $50.8M | −$93.8M | −$74.5M | $62.6M | $28.0M |
| Current ratio | 2.5x | 2.0x | 3.2x | 7.3x | 5.2x |
| Interest coverage | — | — | — | −32.8x | — |
| Returns and quality | |||||
| Return on equity | −111.9% | — | — | — | −92.1% |
| Return on tangible equity | −90.1% | — | — | −27.8% | −149.1% |
| Piotroski F-score | 2 | — | — | 2 | 2 |
| Altman Z'' | −3.9 | −11.9 | −45.9 | 3.7 | −5.6 |
Insiders bought, 12 months
$0.8M
2 insiders
Insiders sold, 12 months
$13.8M
3 insiders
Of sales under plans
100%
$13.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Palvella Therapeutics, Inc. · PVLA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $125.10 a share, the company is worth $1.8B.
Source: SEC EDGAR XBRL filings (CIK 0001583648). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.